论文部分内容阅读
目的 :观察金双歧治疗乙肝肝硬化的疗效 ,其改善症状、体征及肝功能的效应。方法 :86例住院的乙肝肝硬化患者随机分为试验组 (43例 )与对照组 (43例 ) ,试验组在普通支持疗法的基础上加用金双歧片 12片 /日 ,对照组仅用普通支持疗法 ,疗程均为 2个月。疗程结束后 ,比较两组症状、体征及肝功能改善情况。结果 :治疗后 ,试验组、腹胀、腹泻及便秘症状的缓解率均明显高于对照组 (P<0 .0 1) ,纳差、乏力症状的缓解率高于对照组 (P>0 .0 5 ) ;试验组的 AL T复常率、TBil复常率明显高于对照组 (P<0 .0 1) ,血氨及Child- Pugh分数试验组明显低于对照组 (P<0 .0 1) ;AST复常率、AL B复常率高于对照组 ,但无统计学意义 (P<0 .0 5 )。结论 :金双歧治疗乙肝肝硬化安全有效 ,其疗效优于普通支持疗法
Objective: To observe the curative effect of Jinshuangqi on hepatitis B cirrhosis, and to improve the symptoms, signs and the effect of liver function. Methods: Eighty-six patients with hepatitis B cirrhosis were randomly divided into experimental group (43 cases) and control group (43 cases). The experimental group received 12 tablets of Jin Bifu tablets on the basis of general supportive therapy, while the control group received only ordinary Support therapy, treatment are 2 months. After treatment, the symptoms, signs and improvement of liver function in both groups were compared. Results: After treatment, the relief rate of symptoms, abdominal distension, diarrhea and constipation were significantly higher in the experimental group than in the control group (P <0.01) 5); ALT normalization rate and TBil normalization rate in the experimental group were significantly higher than those in the control group (P <0.01), serum ammonia and Child-Pugh score test group was significantly lower than the control group (P <0. 0 1); AST normalization rate, AL B normalization rate was higher than the control group, but not statistically significant (P <0.05). Conclusion: Jinshuangqi safe and effective treatment of hepatitis B cirrhosis, its efficacy is superior to the general supportive therapy